According to the lawsuit, throughout the Class Period, the Company and its senior executives misled investors and/or failed to disclose that: (1) TransMedics used kickbacks, fraudulent overbilling, ...

New York, New York-- (Newsfile Corp. - March 13, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX) ...

TransMedics Group (NASDAQ:TMDX – Get Free Report)‘s stock had its “buy” rating restated by Canaccord Genuity Group in a ...

We recently published a list of 10 Worst Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are ...

Despite recent market volatility, now is the time to be aggressive in investing. Check out five stocks I'll be adding to if ...

TransMedics is revolutionizing organ transplant therapy with its FDA-approved Organ Care System. See why I rate TMDX stock as a buy.

TransMedics Group Inc (TMDX) reports a robust 50% year-over-year revenue growth, improved profitability, and strategic ...

The Allegations: Robbins LLP is Investigating Allegations that TransMedics Group, Inc. (TMDX) Misled Investors Regarding its Coercive and Unsafe Business Practices According to the complaint ...

TMDX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false ...

It's been a rough several months for TransMedics Group (NASDAQ: TMDX) shareholders. The stock has been beaten down by about ...

On this news, the price of TransMedics stock fell $3.74 per share, or 5.15%, to close at $68.81 on January 10, 2025. On January 13, 2025, TransMedics stock fell a further $4.76 per share, or 6.9%, to ...

This report further depressed the company's stock price, the lawsuit claims. Prominent investor rights firm Hagens Berman Sobol Shapiro LLP is probing whether TransMedics misled investors regarding ...